Cardio-HART™ - a Breakthrough Cardiac-Telemedicine™ device, now CE-Marked

Just in time to meet the consequences of COVID-19-caused heart disease, CHART has obtained CE Mark certification for use in the EU. 

Telemedicine is the future of patient visits to the doctor, especially in this pandemic as it helps maintain social distancing safety guidelines. This will be critical in the face of the feared second wave of COVID-19. Healthcare systems, slow to move to telemedicine before the pandemic, have dropped all pretense of caution as social distancing through telemedicine makes healthcare workers safer, without being any less effective for the patient, and is now the main model for Primary Care.

CHART is Cardiac-Telemedicine™ at its best, transforming Primary care into the new front line of heart care, to meet the post-pandemic needs of all Europeans. 

The divide between Primary Care and Cardiology Care, the next level of care, was always a major unmet medical need, tolerated only because of a lack of an effective, easy-to-use, medical device that could help bridge the gap. At 44%, the traditional ECG/EKG devices were simply never sufficiently effective pre-pandemic and will be virtually useless in a post-pandemic telemedicine environment.

Our solution for Cardiac-Telemedicine™ is…

Cardio-HART™ (a.k.a. “CHART”)

CHART goes beyond the 44% limitations of traditional ECG/EKG... complementing and augmenting its capabilities, able to detect and diagnose up to 95% of all common heart diseases, by prevalence typically found in Primary Care situations without changing the Standard of Care.

CHART will help ensure that affected patients are not left behind, forgotten, and neglected in the shadow of COVID-19, or its dreaded second wave. 

In a recent clinical study, conducted on over 500 patients, GPs increased their diagnostic effectiveness by some 250% over the most advanced traditional ECG/EKG systems. This resulted in a 24% reduction in FN and a 14% reduction in FP. These are numbers that GPs in Telemedicine need, to fight the legacy of COVID-19-induced heart disease, and reduce the burden on a re-building healthcare system.   

And with a much dreaded second imminent wave of COVID-19, heart disease needs to be detected earlier and faster to help mitigate the long-term morbidity potential and ongoing healthcare system costs that could threaten to undermine the effectiveness and access of Europe’s healthcare systems.